CD274 and head and neck squamous cell carcinoma: Targeting the programmed cell death (ligand)-1 (PD-(L)1) pathway has shown significant activity, and improved overall survival (OS) in patients with previously treated R/M HNSCC, associated with fewer grades 3 or 4 toxicities than standard therapy (4, 5).